UA73959C2 - Grinded form of (s)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy]phenyl)]propane acid, a method for the preparation thereof and a pharmaceutical composition - Google Patents

Grinded form of (s)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy]phenyl)]propane acid, a method for the preparation thereof and a pharmaceutical composition Download PDF

Info

Publication number
UA73959C2
UA73959C2 UA2002053989A UA2002053989A UA73959C2 UA 73959 C2 UA73959 C2 UA 73959C2 UA 2002053989 A UA2002053989 A UA 2002053989A UA 2002053989 A UA2002053989 A UA 2002053989A UA 73959 C2 UA73959 C2 UA 73959C2
Authority
UA
Ukraine
Prior art keywords
ethoxy
pharmaceutically acceptable
acceptable salt
formula
solvate
Prior art date
Application number
UA2002053989A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UA73959C2 publication Critical patent/UA73959C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UA2002053989A 1999-12-03 2000-11-29 Grinded form of (s)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy]phenyl)]propane acid, a method for the preparation thereof and a pharmaceutical composition UA73959C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904413A SE9904413D0 (sv) 1999-12-03 1999-12-03 Comminuted form
PCT/SE2000/002381 WO2001040169A1 (en) 1999-12-03 2000-11-29 Comminuted form of (s)-2-ethoxy -3-[4-(2- {4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid

Publications (1)

Publication Number Publication Date
UA73959C2 true UA73959C2 (en) 2005-10-17

Family

ID=20417978

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2002053989A UA73959C2 (en) 1999-12-03 2000-11-29 Grinded form of (s)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy]phenyl)]propane acid, a method for the preparation thereof and a pharmaceutical composition

Country Status (32)

Country Link
EP (1) EP1237854B1 (cs)
JP (1) JP2003515580A (cs)
KR (1) KR20020067538A (cs)
CN (1) CN1216859C (cs)
AR (1) AR029456A1 (cs)
AT (1) ATE251131T1 (cs)
AU (1) AU766036B2 (cs)
BR (1) BR0016135A (cs)
CA (1) CA2392029A1 (cs)
CO (1) CO5271736A1 (cs)
CZ (1) CZ20021839A3 (cs)
DE (1) DE60005710T2 (cs)
DK (1) DK1237854T3 (cs)
EE (1) EE200200284A (cs)
ES (1) ES2208444T3 (cs)
HK (1) HK1049324B (cs)
HU (1) HUP0203692A3 (cs)
IL (1) IL149516A0 (cs)
IS (1) IS6399A (cs)
MX (1) MXPA02005165A (cs)
MY (1) MY125099A (cs)
NO (1) NO20022591D0 (cs)
NZ (1) NZ518926A (cs)
PL (1) PL355372A1 (cs)
PT (1) PT1237854E (cs)
RU (1) RU2248966C2 (cs)
SE (1) SE9904413D0 (cs)
SK (1) SK7662002A3 (cs)
TR (1) TR200400003T4 (cs)
UA (1) UA73959C2 (cs)
WO (1) WO2001040169A1 (cs)
ZA (1) ZA200203797B (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
AU1198699A (en) 1997-10-27 1999-04-23 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
BR9812770A (pt) 1997-10-27 2000-12-12 Reddy Research Foundation Compostos bicìclicos, processo para seu preparo e composições farmacêuticas contendo os mesmos
PL193086B1 (pl) 1997-10-27 2007-01-31 Reddys Lab Ltd Dr Nowe związki tricykliczne i związki pośrednie, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
UA60386C2 (uk) 1998-10-29 2003-10-15 Reddys Laboratories Ltd Спосіб одержання похідних 3-[4-[2-(феноксазин-10-іл)метокси]феніл]пропіонової кислоти (варіанти) та проміжні сполуки для їх отримання
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
BRPI0416639A (pt) 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
CN101511364B (zh) 2006-09-07 2012-08-15 奈科明有限责任公司 用于糖尿病的治疗组合
PT2125711E (pt) 2007-03-08 2014-02-05 Albireo Ab Pirimidinas como inibidores de quinase
WO2008149345A2 (en) 2007-06-04 2008-12-11 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
CN106061940A (zh) 2013-11-05 2016-10-26 本古里安大学内盖夫研究发展局 治疗糖尿病和由其引发的并发疾病的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
SE9704873D0 (sv) * 1997-12-23 1997-12-23 Astra Ab Sampling apparatus
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues

Also Published As

Publication number Publication date
HUP0203692A2 (hu) 2003-03-28
ZA200203797B (en) 2003-08-13
IL149516A0 (en) 2002-11-10
CZ20021839A3 (cs) 2002-08-14
EP1237854A1 (en) 2002-09-11
TR200400003T4 (tr) 2004-02-23
CO5271736A1 (es) 2003-04-30
DE60005710D1 (en) 2003-11-06
IS6399A (is) 2002-05-28
NO20022591L (no) 2002-05-31
RU2002113169A (ru) 2004-01-20
HK1049324B (en) 2004-04-30
AR029456A1 (es) 2003-07-02
WO2001040169A1 (en) 2001-06-07
ES2208444T3 (es) 2004-06-16
BR0016135A (pt) 2002-08-20
SK7662002A3 (en) 2002-10-08
PL355372A1 (en) 2004-04-19
CN1216859C (zh) 2005-08-31
PT1237854E (pt) 2004-02-27
EP1237854B1 (en) 2003-10-01
DE60005710T2 (de) 2004-08-05
HUP0203692A3 (en) 2005-05-30
NZ518926A (en) 2003-11-28
JP2003515580A (ja) 2003-05-07
SE9904413D0 (sv) 1999-12-03
MXPA02005165A (es) 2003-09-25
RU2248966C2 (ru) 2005-03-27
EE200200284A (et) 2003-08-15
CA2392029A1 (en) 2001-06-07
ATE251131T1 (de) 2003-10-15
AU766036B2 (en) 2003-10-09
KR20020067538A (ko) 2002-08-22
HK1049324A1 (en) 2003-05-09
CN1402704A (zh) 2003-03-12
DK1237854T3 (da) 2004-01-12
NO20022591D0 (no) 2002-05-31
AU2034801A (en) 2001-06-12
MY125099A (en) 2006-07-31

Similar Documents

Publication Publication Date Title
UA73959C2 (en) Grinded form of (s)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy]phenyl)]propane acid, a method for the preparation thereof and a pharmaceutical composition
JP6043758B2 (ja) 酢酸リカルバゼピンを含む経口剤形
TWI417098B (zh) （阿伐ｓ，貝他ｒ）-６-溴-阿伐-〔２-（二甲胺基）乙基〕-２-甲氧基-阿伐-１-萘-貝他-苯基-３-喹啉乙醇
JPH0548206B2 (cs)
CN108601751A (zh) 雷公藤红素的类似物
SK12692001A3 (sk) Zmesi valdecoxibu
HUE027664T2 (en) Nalbuphine-based formulations and uses thereof
JP3444597B2 (ja) 医薬品組成物の製造法
US20090136570A1 (en) Taste-Masked Tablets and Granules
CN1128999A (zh) 杂环化合物
US7084177B2 (en) Comminuted form of(S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid
TW200803854A (en) Pharmaceutical compositions
TWI481590B (zh) 作為ｍｅｋ抑制劑之ｎ－（芳胺基）磺醯胺（包括多晶型）衍生物及組合物，使用方法及其製備方法
US20110178174A1 (en) Salts of tramadol and ibuprofen and their crystal form in the treatment of pain
JP2025524090A (ja) ｎｏｒ－ＵＤＣＡの医薬組成物
JPS5955829A (ja) 脳内の器質性障害に起因する精神機能症状の改善・治療剤
JPS6041690A (ja) １―チオ―β―Ｄ―グルクロン酸誘導体およびその製法
EP2266948A1 (en) Salts of tramadol and diflunisal and their crystal form in the treatment of pain
JPS5927887A (ja) ジチオラン誘導体及び肝臓疾患治療剤
JPH0452263B2 (cs)
WO2005117840A1 (en) Stable pharmaceutical compositions comprising pulverized granules of nateglinide of form b